About the Penn Center for Precision Medicine

The Penn Center for Precision Medicine (PCPM) works to enhance the development of precision medicine efforts, as well as implement precision-medicine-based clinical care in the fabric of routine care.

We hope to forge strong interconnections between the people who are making impactful scientific discoveries every day and the clinicians and clinical teams delivering outstanding care. We also serve as a source of information for both programs and centers within the health system and for organizations outside that wish to explore partnerships with us.

To accomplish these goals and advance precision medicine, we have the following four initiatives in place:


Measure Outcomes

We bring together an interdisciplinary team with expertise in data analysis, biostatistics and health economics to allow us to measure both biological (medical) and economic (cost and cost avoidance) outcomes. These measurements will be critical to evaluate the success of our efforts.

Build Infrastructure to Maximize Synergies

We’re building a structure that will better integrate efforts, break up silos and achieve more synergy. This infrastructure includes:

  • A fellows program to help faculty leaders vet and develop precision medicine projects
  • Two assistant directors tasked with bringing clinicians, physician-scientists and researchers together
  • An “accelerator fund”, designed to support projects that test novel, interdisciplinary precision medicine approaches that directly impact patient care
  • A translational innovation laboratory to help us continuously innovate and accelerate the translation and validation of cutting-edge diagnostic technology

Integrate Precision Medicine in Patient Care

Our biggest goal is to translate the advances in precision medicine into daily care for our patients. We’re employing “demonstration projects” to bring precision medicine into routine patient operations and measure their impact.

Present an Outward-Facing Presence

We’ll communicate Penn’s leadership in precision medicine to internal staff and to the broader public via online and social media outreach and an annual symposium.

Request for Applications

Penn Center for Precision Medicine Accelerator Fund Projects

The PCPM Accelerator Fund is currently seeking requests for application that will accelerate development of precision medicine efforts at Penn and help to implement precision medicine-based clinical care in the fabric of routine care provided by the health system.

The PCPM welcomes all applications that focus on bringing a particular precision medicine approach to clinical care. Project descriptions should be supported by preliminary data demonstrating the viability of the approach under laboratory conditions. Please note that for purposes of this process, “precision medicine” is broadly defined, and includes a variety of approaches to phenotype patients and personalized care (including genetics, genomics, other ‘omics, biomarkers, imaging, computational approaches, wearable devices, etc.)

Review Criteria will include:

  1. Impact: What is the likelihood that the proposed program of will translate precision medicine based approaches to clinical practice and have a transformative impact on patient care?
  2. Impact on Penn Medicine: How will this project impact the delivery of patient care and/or health economics across Penn Medicine?
  3. Innovation: Is the proposal creative and original? If successful, will the work produce dramatic shifts in clinical practice, improving our ability to deliver individualized care by using novel concepts, methodologies, and/or interventions? Will the innovation help to decrease health care costs?
  4. Investigative Team: Do the proposed PIs have a strong track record of leadership of interdisciplinary and translational science? Does the team have sufficient interdisciplinary breadth and depth to carry out the proposed research?
  5. Approach: Are the general strategies and translational approaches sufficiently rigorous to ensure generation clinical efficacy, financial cost/opportunity data? Are reasonable metrics of success articulated?

Presubmission inquiries about proposals are welcome; please put “precision medicine proposal” in the title of your email (mailto:joshua.lubin@uphs.upenn.edu).

Application Instructions:

  1. Please refer to the detailed application guidelines (PDF).
  2. Submit detailed Letter of Intent to the Chief Administrative Officer of the Penn Center for Precision Medicine, Joshua Lubin, at joshua.lubin@uphs.upenn.edu by February 1, 2017 by 5 PM


Welcome Joshua Lubin, MBA

The Penn Center for Precision Medicine (PCPM) is pleased to announce the appointment of Joshua Lubin, MBA, as Chief Administrative Officer of the newly established PCPM. In this capacity, he will work closely with David B. Roth, MD, PhD, Director of the Penn Center for Precision Medicine, and the many stakeholders invested in this field to accelerate the implementation of precision medicine into clinical care.


Joshua Lubin has extensive experience in medical school administration, research administration, and healthcare administration. He most recently served as Director of Operations and then Chief Operating Officer at the Rowan University School of Osteopathic Medicine (formerly UMDNJ). Prior to Rowan University, he held successive managerial and leadership positions at Thomas Jefferson University Hospitals, including Administrator at the Kimmel Cancer Center, where he was responsible for the financial and operational oversight for three departments, including two wet-bench research departments, one clinical research division, and 12 research core facilities, as Research Administrator at the Office of Research Administration, and as Hospital Grants Administrator, where he was responsible for the pre- and post-award administration of large grants for both clinicians and clinical trials and for basic scientists. He received his Master of Business Administration with a focus on health, health-care administration, and management from Rosemont College in 2006 and is a member of the American College of Healthcare Executives (ACHE).

Joshua Lubin will have overall responsibility for the successful development, implementation and advancement of the operational, strategic, and programmatic initiatives of the PCPM, interfacing between the research environment at the School of Medicine and project implementation in the context of the clinical enterprise with a varied set of stakeholders across UPHS. We are delighted to have him on board.

Welcome Abigail Tripp Berman, MD, MSCE

The Penn Center for Precision Medicine (PCPM) is pleased to announce the appointment of Abigail Tripp Berman, MD, MSCE, Assistant Professor of Radiation Oncology, as Associate Director, Clinical, of the newly established PCPM. In this capacity, she will work closely with David B. Roth, MD, PhD, Director of the Penn Center for Precision Medicine, and the many stakeholders invested in this field to accelerate the implementation of precision medicine into clinical care.


Dr. Berman earned her A.B. in Chemistry at Harvard University, and her Medical Degree and Masters of Science in Clinical Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She completed her medicine internship and radiation oncology residency at the University of Pennsylvania. She specializes in the treatment of patients with lung cancer and other thoracic malignancies with photon and proton radiation therapy and has research expertise in translational thoracic radiation oncology and clinical trials with multi-modality therapy. Dr. Berman has received research funding from the National Institutes of Health and the Radiologic Society of North America. She is the director of the medical student Radiation Oncology clerkship and Co-Director of Clinical Trials in Oncology Course and Workshop. She is a member of the ITMIG Thymic Carcinoma Workgroup and on the Editorial Board of RadOnc Questions and Frontiers in Oncology.

The PCPM was developed by Dr. Roth and senior leaders at Penn Medicine to create and implement precision medicine-based clinical care pathways embedded in systems of care and to facilitate practice-changing research by making robust connections between various groups working at Penn. The PCPM will implement accelerator fund and implementation projects to bring precision medicine into routine UPHS operations and measure their impact. The PCPM has broad support from the EVP/Dean and PSOM leadership.

In her role as Associate Director, Clinical, Dr. Berman will be responsible for helping to create and sustain robust interfaces between clinicians and their clinical needs and those of basic or translational researchers. She will help the PCPM develop and actualize the implementation projects vetted by the Internal Advisory Board and others into clinical operations of the Health System and will work with the PCPM’s Outcomes Measurement team and other team members to monitor other precision-medicine projects, including those funded by the accelerator fund.

We are certain that Dr. Berman’s drive, commitment and vision will continue to energize the faculty and help Penn and the PCPM to achieve national preeminence in the rapidly expanding field of precision medicine.

David B. Roth, MD, PhD
Simon Flexner Professor and Chair of Pathology and Laboratory Medicine
Director, Penn Center for Precision Medicine
University of Pennsylvania Perelman School of Medicine


Meet Our Precision Medicine Team



David B. Roth, MD, PhD

Director, Penn Center for Precision Medicine
Chair, Department of Pathology and Laboratory Medicine
Genomic alterations in cancer


Abigail Tripp Berman, MD, MSCE

Assistant Professor of Radiation Oncology
Associate Director, Clinical, Penn Center for Precision Medicine
Translational thoracic radiation oncology


Sara Cherry, PhD

Associate Professor of Microbiology
Director, Chemogenomic Discovery Program, Penn Center for Precision Medicine
Genetic and mechanistic studies of viral-host interactions




Kevin B. Mahoney, MBA

Executive Vice President, Chief Administrative Officer
Executive Vice Dean for Integrative Services
Penn Medicine


Katherine L. Nathanson, MD

Chief Oncogenomics Physician, Abramson Cancer Center
Somatic and inherited genetics of cancer


Joshua Lubin, MBA

Chief Administrative Officer, Penn Center for Precision Medicine




Jason H. Moore, PhD

Director, Institute for Biomedical Informatics
Translational bioinformatics, computational genomics


Daniel J. Rader, MD

Chair, Department of Genetics
Genetics of cardiovascular disease


Mitchell D. Schnall, MD, PhD

Chair, Department of Radiology
Cancer Imaging

2016-17 Precision Medicine Accelerator Fund Projects


Measuring the Impact of ctDNA NGS on Clinical Decision Making for NSCLC Patients




  • Erica L. Carpenter, MBA, PhD
    Department of Medicine, Division of Hematology and Oncology
  • Charu Aggarwal, MD
    Department of Medicine, Division of Hematology and Oncology


  • Kojo Elenitoba-Johnson, MD
    Center for Personalized Diagnostics
  • Sharyn Katz, MD
    MTR Radiology
  • Corey Langer, MD
  • Jennifer Morrissette, PhD
    Center for Personalized Diagnostics
  • Andrea Troxel, ScD
    Biostatistics and Epidemiology

A Pharmacogenetic Approach to Parkinson’s Disease



  • Alice Chen-Plotkin, MD
    Department of Neurology


  • Daniel Weintraub, MD
  • Vivianna Van Deerlin, MD, PhD
    Pathology and Laboratory Medicine
  • Allison Willis, MD
    Department of Neurology

Optimizing Antimicrobial Prescribing Using a Precision Antibiogram



  • Keith William Hamilton, MD
    Department of Medicine, Division of Infectious Diseases


  • Valerie Cluzet, MD
    Division of Infectious Diseases
  • Kevin Alby, PhD
    Pathology and Laboratory Medicine

Precision Medicine and Digital Media: Exploring Applications for Clinical Care



  • Raina M. Merchant, MD, MSHP, FAHA
    Department of Emergency Medicine


  • David Asch, MD, MBA
    Department of Medicine
  • David Grande, MD, MPA
    Leonard Davis Institute for Health Economics
  • Lyle Ungar, PhD
    Computer and Information Science

PARP Inhibition in Advanced Breast Cancer with non-BRCA-associated Deficient Homologous Recombination



  • Payal D. Shah, MD
    Department of Medicine, Division of Hematology and Oncology


  • Susan M. Domchek, MD
    Basser Professor in Oncology
  • Katherine L. Nathanson, MD
    Department of Medicine
  • Kara Maxwell, MD, PhD
    Department of Medicine

Prehabilitation to Improve Postoperative Outcomes and Limit Complications



  • Carsten C. Skarke, MD
    Department of Medicine and Department of Systems Pharmacology and Translational Therapeutics


  • Nalaka Gooneratne, MD, MSs
    Department of Medicine
  • Junxin Li, PhD
    Department of Medicine
  • Greg Grant, PhD
    Department of Genetics
  • Jason H. Moore, PhD
    Department of Biostatistics and Epidemiology
  • Garret A. FitzGerald, MD
    Institute for Translational Medicine and Therapeutics (ITMAT)
  • Elizabeth Mahanna, MD
    Department of Anesthesiology and Critical Care
  • Gwo-Chin Lee, MD
    Department of Orthopedics
  • Yvette Sheline, MD
    Department of Psychiatry

Actionable Pharmacogenetic (PGx) Variants in the University of Pennsylvania Health System



  • Sony Tuteja, PharmD, MS
    Department of Medicine, Division of Translational Medicine and Human Genetics


  • Daniel J. Rader, MD
    Department of Medicine
  • Sean Hennessy, PharmD, PhD
    Department of Biostatistics and Epidemiology
  • Peter E. Gabriel, MD, MSE
    Department of Radiation Oncology
  • Katharine Bar, MD
    Department of Medicine

UsingT1rho MRI as a Surrogate for Detection of Early Cartilage Degeneration and Guide for Early Intervention in Patellofemoral Pain



  • Miltiadis H. Zgonis, MD
    Department of Orthopaedic Surgery


  • Ravinder Reddy, PhD
    Department of Radiology
  • J. Bruce Kneeland, MD
    Department of Radiology



Penn Links

  • Clinical Trials at Penn Medicine
    Information about clinical trials at Penn Medicine and contact information for the Office of Clinical Research at the Perelman School of Medicine at the University of Pennsylvania.
  • Penn Center for Innovation in Personalized Cancer Screening
    A collaboration between general medicine, family medicine and Radiology focusing on precision approaches to breast cancer screening. The PCIPS collects and aggregates data on more than 74,000 women within Penn Medicine's health care network, along with data from Pennsylvania state breast cancer registries.
  • Penn CPD
    The Center for Personalized Diagnostics (CPD) is a joint initiative between Penn Medicine's Department of Pathology and Laboratory Medicine and the Abramson Cancer Center to support precision medicine at Penn. The CPD aims to uncover genetic mutations within a patient's own cancer that can allow for a more targeted and personalized "precision" treatment strategy by integrating molecular genetics, pathology informatics, and genomic pathology.
  • Penn Institute for Bioinformatics
    The mission of the institute for Biomedical Informatics (IBI) at the Perelman School of Medicine of the University of Pennsylvania is to provide an interdisciplinary home for faculty, staff and students interested in bioinformatics, clinical informatics, clinical research informatics, consumer health informatics, and public health informatics. The goal is to improve healthcare and fundamental knowledge of biological systems by creating an informatics ecosystem through cutting-edge educational programs, computational infrastructure, and collaborative research.
  • Center for Biomedical Image Computing and Analytics
    The Center for Biomedical Image Computing and Analytics (CBICA) develops and applies advanced computational and analytical techniques that quantify morphology and function from biomedical images, and integrates imaging phenotypes with genetic and molecular data, producing into diagnostic and predictive tools to enable precision medicine.
  • Congenital Hyperinsulinism Center
    Children with congenital hyperinsulinism may often have focal disease within the pancreas. 18F-DOPA is taken up by functioning islet cells and can identify patients with focal disease. Visualizing focal disease provides an opportunity for a surgical cure.
  • Penn Center for Precision Surgery
    The Penn Center for Precision Surgery works with a promising new investigational technique for solid tumors. The technique is intended to help surgeons see the entire tumor, and help detect cancer cells that could otherwise be missed during surgery. It is now being tested by surgeons and oncologists at the Center for Precision Surgery at Penn Medicine’s Abramson Cancer Center. If approved by the FDA this new approach, called Intraoperative molecular imaging, would help with early detection and hopefully better treatment success for cancer patients.
  • Basser Center for BRCA
    The Basser Center for BRCA is the only center in the world solely devoted to BRCA-related cancers. It is a global hub, a place for families to become educated and receive genetic counseling, and simultaneously a center for breakthroughs and discoveries.
  • Penn Medicine BioBank
    The Penn Medicine BioBank supports researchers by providing centralized access to a large number of annotated blood and tissue samples. This bank of samples and linked data will be an invaluable resource to the Penn Medicine basic, translational, and clinical research communities. Ultimately, this approach will enhance knowledge regarding the genetic and pathophysiological basis of multiple disease processes and will permit improved preventive and therapeutic strategies.
  • Preventive Cardiovascular Program
    Penn Medicine's Preventive Cardiovascular Program strives to prevent the onset, recurrence, and progression of heart and vascular disease using medications and lifestyle changes tailored to maximize efficacy and minimize side effects through personalized cardiovascular risk assessment.
  • Penn Data Analytics Center
    The Penn Data Analytics Center is an enterprise-wide group centered on decision support, data access, and data visualization. The DAC team of experienced personnel is responsible for guiding customers through the challenges of requirements gathering and decision making and on to the realized end-product – whether this is a complete enterprise dashboard solution, additions to our data warehouse(s), or an ad-hoc report request. The Data Analytics Center leverages Penn's massive stores of data to help everyone from corporate administration to researchers make better decisions to achieve all three missions of Penn Medicine.
  • Center for Rare Cancers and Personalized Therapy
    Opened in 2015 as part of the Abramson Cancer Center, this virtual center enrolls patients into clinical trials based on genetic markers rather than tumor origin. Patients with the same mutation but different cancers will be included in the same clinical study to investigate a targeted therapy.
  • Penn Orphan Disease Center
    The Orphan Disease Center is developing transformative therapies using platform technologies that can be deployed across multiple rare diseases. We emphasize disorders with substantial unmet need independent of their incidence and strive to assure access to patients of all populations. The focus of the Center lies in partnership and leveraging of resources.
  • Penn CHOP Microbiome Program 2017 Pilot & Feasibility Grants
    The goals of the Microbiome Program are to understand the human microbiome and alter its properties to improve health. The Human Microbiome Project is the largest project ever in Microbiology, and has been prominently advanced by work at Penn and CHOP.
  • Penn Center for Health Care Innovation
    The Penn Medicine Center for Health Care Innovation facilitates the rapid, disciplined development, testing and implementation of new strategies to reimagine health care delivery for dramatically better value and patient outcomes.



External Links


Contact Information

For development questions, contact Kathryn J. Griffo, Chief Advancement Officer, at 215-898-3653 or kgriffo@upenn.edu. For participation in the PCPM or other precision-medicine related questions, please contact Dr. David Roth at David.Roth2@uphs.upenn.edu.